Welcome to our dedicated page for Scynexis news (Ticker: SCYX), a resource for investors and traders seeking the latest updates and insights on Scynexis stock.
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company developing antifungal medicines based on its proprietary triterpenoid antifungal platform known as "fungerps." News about SCYNEXIS frequently centers on clinical data, regulatory interactions, collaborations, and its exclusive license agreement with GSK for ibrexafungerp, the active ingredient in the FDA-approved product BREXAFEMME for vulvovaginal candidiasis and reduction in the incidence of recurrent VVC.
On this page, readers can follow company announcements related to the development of next-generation fungerps, including SCY-247, which SCYNEXIS describes as a second-generation triterpenoid antifungal under clinical and preclinical evaluation for invasive fungal infections. Recent updates have highlighted positive Phase 1 single and multiple ascending dose results, preclinical data presented at scientific congresses, and plans for additional studies using both oral and intravenous formulations.
SCYNEXIS news also covers key events in its collaboration with GSK, such as the transfer of the BREXAFEMME New Drug Application, resolution of disagreements regarding the Phase 3 MARIO study in invasive candidiasis, and associated milestone or other payments. Regulatory and listing developments, including Nasdaq minimum bid price notices and extensions to regain compliance, are disclosed through company press releases and SEC filings.
Investors, clinicians, and researchers can use this news feed to review updates on clinical trial progress, antifungal data presentations, license agreement developments, and corporate milestones. Regularly checking this page helps users track how SCYNEXIS advances its fungerp platform, manages its partnership with GSK, and responds to regulatory and market requirements.
SCYNEXIS, Inc. announces its antifungal drug, ibrexafungerp, aligns with BARDA's new initiative to develop broad-spectrum antifungal agents targeting drug-resistant fungi like Candida and Aspergillus. This follows BARDA's focus on innovative treatments amid rising fungal threats, highlighted by the WHO's recent report on dangerous pathogens. Ibrexafungerp has shown effectiveness against resistant strains and is in late-stage trials with FDA support. SCYNEXIS aims to address severe fungal infections, enhancing treatment options for patients.
SCYNEXIS is refocusing on ibrexafungerp for severe hospital-based indications. Ivor Macleod joins as CFO, while Marco Taglietti retires as CEO, with David Angulo stepping in from January 1, 2023. In Q3 2022, BREXAFEMME generated net revenues of $1.6 million, a 13% increase from Q2 2022. Coverage rose to 130 million lives, or 70% of commercially insured lives. The company has $96.1 million in cash, ensuring a runway into Q2 2024, and is pursuing commercialization partnerships for BREXAFEMME.
SCYNEXIS, Inc. has published a review highlighting the antifungal ibrexafungerp's potential against deadly fungal infections listed by the WHO. This novel treatment shows promise for immunocompromised patients facing invasive mold infections. Ibrexafungerp is noted for its effectiveness against drug-resistant species and its convenient oral dosing. Ongoing clinical trials aim to further validate its efficacy in treating mold infections. The widespread resistance to current antifungal treatments underscores the urgent need for novel therapies like ibrexafungerp.
SCYNEXIS announced positive results from a pooled analysis of two Phase 3 studies, VANISH-303 and VANISH-306, published in the Journal of Women’s Health. Ibrexafungerp demonstrated statistically significant superior clinical cure rates, complete symptom resolution, and mycological cure compared to placebo (p 0.0001). The data supports its potential as an effective treatment for vulvovaginal candidiasis (VVC), indicating consistent efficacy across various patient sub-populations. Ibrexafungerp is well-tolerated with mild gastrointestinal adverse events.
SCYNEXIS, Inc. (NASDAQ: SCYX) has scheduled a conference call for November 9, 2022, at 8:30 a.m. EDT to discuss its third-quarter financial results for the period ending September 30, 2022. The company, focused on developing innovative medicines for drug-resistant infections, has received FDA approval for its antifungal product, BREXAFEMME, and filed a supplemental New Drug Application for expanded indications, with a target FDA action date of November 30, 2022. The call will also provide corporate updates and insights into ongoing clinical trials.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced the appointment of Ivor Macleod as Chief Financial Officer, bringing over 30 years of biopharma experience. Macleod will support the company's strategic shift towards hospital-based antifungal treatments, specifically ibrexafungerp, a first-in-class antifungal agent. He previously served as CFO at Athersys, Inc. and Eisai Inc. In connection with his appointment, he received stock options for 170,000 shares at $2.22 and 15,000 RSUs. The company also aims to expand BREXAFEMME's labeling to prevent recurrent vulvovaginal candidiasis, with a PDUFA date set for November 30, 2022.
SCYNEXIS, Inc. (NASDAQ: SCYX) presented interim results from the ongoing Phase 3 FURI study at IDWeek 2022, showing positive clinical outcomes from ibrexafungerp treatment. The study highlights an 82.3% positive outcome rate across various fungal diseases and a 94.6% survival rate at 30 days post-treatment for patients with invasive candidiasis. With data from 113 patients, most had invasive candidiasis/candidemia, demonstrating significant therapeutic response rates. SCYNEXIS aims for salvage therapy indication, reinforcing its commitment to developing ibrexafungerp to address challenging fungal infections.
SCYNEXIS (NASDAQ: SCYX) has announced a new strategic direction to focus on the clinical development of ibrexafungerp for severe, hospital-based fungal infections, with first approval anticipated in 2024. The company plans to out-license BREXAFEMME for vulvovaginal candidiasis (VVC) while winding down promotional activities and concluding its partnership with Amplity Health, leading to a workforce reduction. These moves aim to extend the cash runway into Q2 2024. Additionally, SCYNEXIS is undergoing changes in executive leadership with a new CEO taking charge in January 2023.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced that interim data from the Phase 3 FURI study on oral ibrexafungerp will be presented at IDWeek 2022 in Washington, D.C., from October 19-23, 2022. The presentations will cover all-cause mortality in patients with invasive candidiasis and outcomes by fungal disease, emphasizing ibrexafungerp's potential in treating drug-resistant infections. Ibrexafungerp, a novel antifungal agent, is in late-stage development for severe fungal infections and received multiple designations from the FDA and EMA to expedite its path to market.
SCYNEXIS, Inc. (NASDAQ: SCYX) announced that Marco Taglietti, President and CEO, will present at the H.C. Wainwright Annual Global Investment Conference on September 14, 2022, from 3:30 p.m. to 4:00 p.m. EDT, and at the Ladenburg Thalmann Annual Healthcare Conference on September 29, 2022, from 12:00 p.m. to 12:25 p.m. EDT. Both presentations will include company insights and 1:1 meetings with attendees. SCYNEXIS focuses on innovative medicines to combat drug-resistant infections, with their lead product, BREXAFEMME, approved by the FDA on June 1, 2021.